Navigation Links
Perrigo Confirms Filing for Generic Version of VANOS(R)
Date:6/9/2008

ALLEGAN, Mich., June 9 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has filed an Abbreviated New Drug Application (ANDA) for Fluocinonide Cream 0.1%, a generic version of VANOS(R) Cream 0.1%. The Company believes that it is the first to file an ANDA with a Paragraph IV certification against VANOS(R).

VANOS(R) (fluocinonide) Cream 0.1% is a corticosteroid (steroid hormone) approved to relieve the inflammation and itching caused by certain skin conditions that respond to treatment with corticosteroids in patients 12 years of age or older, and had sales of approximately $27 million for the 12 months ended April 2008, as measured by Wolters Kluwer Health.

Perrigo filed its ANDA for Fluocinonide Cream, 0.1% containing a Paragraph IV Certification with the U.S. Food & Drug Administration and notified Medicis Pharmaceutical Corporation, the listed patent holder of its filing. On June 6, 2008, Medicis filed suit alleging patent infringement in the United States District Court for the Western District of Michigan to prevent Perrigo from proceeding with the commercialization of its product. This action formally initiates the patent process under the Hatch-Waxman Act.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet ( http://www.perrigo.com ).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech
2. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
3. Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal 2008
4. Perrigo Company Announces Quarterly Dividend
5. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
6. Perrigo Company Will Release Third Quarter Fiscal 2008 Results on May 6, 2008
7. Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack
8. Perrigo Company to Present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum
9. Perrigo Company Announces Launch of Clobetasol Propionate Foam
10. Perrigo Company Receives Final Approval on Clobetasol Propionate Foam
11. Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts them at ... Adam and Hal Kimowitz are currently accepting new patients at their practice for these ... for some patients, which is why they offer the latest in modern dental techniques ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... Clinical Innovation Catalyst program focused on finding product improvements that could ... placed in their throats when they need help breathing or to provide medication. ...
(Date:6/20/2017)... Ariz. (PRWEB) , ... June 20, 2017 , ... ... Natural Brands®, makers of SweetLeaf® Stevia Sweetener, Michael P. May, Ph.D., recently accepted ... Sun Corridor Export Recognition Program selected Wisdom Natural Brands (WNB), and 16 other ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... the security systems industry has been selected as the partner of choice by ... a passenger railroad service that provides medium- and long-distance intercity service in the ...
(Date:6/20/2017)... ... June 20, 2017 , ... John D'Eri, CEO of ... Leader in Adult Autism Award during the Autism Society of America 's ... The Daniel Jordan Fiddle Foundation (DJFF) was founded in 2002 as the ...
Breaking Medicine News(10 mins):
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
(Date:5/26/2017)... Calif. , May 25, 2017  In response ... States , Direct Relief is working with Pfizer ... Naloxone available at no cost to community health centers, ... nonprofit providers nationwide. "Pfizer has a ... to medicines and ensuring patient safety through educational activities," ...
(Date:5/23/2017)... 23, 2017  Leaf Healthcare, recognized for developing ... for pressure ulcer prevention, will unveil its comprehensive ... Critical Care Nurses, National Teaching Institute and Critical ... The Leaf Patient Monitoring System is the first ... environment.  The system seamlessly tracks patient movement throughout ...
Breaking Medicine Technology: